Publication: COVID-19 vaccination and cardiac dysfunction
0
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
19498462
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Journal of Preventive Medicine and Public Health. Vol 55, No.4 (2022), p.334-341
Suggested Citation
Leowattana W., Leowattana T. COVID-19 vaccination and cardiac dysfunction. Journal of Preventive Medicine and Public Health. Vol 55, No.4 (2022), p.334-341. doi:10.4330/wjc.v14.i6.343 Retrieved from: https://hdl.handle.net/20.500.14740/10390
Author(s)
Abstract
The coronavirus disease 2019 (COVID-19) mRNA vaccine against severe acute respiratory syndrome coronavirus 2 infections has reduced the number of symptomatic patients globally. A case series of vaccine-related myocarditis or pericarditis has been published with extensive vaccination, most notably in teenagers and young adults. Men seem to be impacted more often, and symptoms commonly occur within 1 wk after immunization. The clinical course is mild in the majority of cases. Based on the evidence, a clinical framework to guide physicians to examine, analyze, identify, and report suspected and confirmed cardiac dysfunction cases is needed. A standardized workup for every patient with strongly suspicious symptoms associated with the COVID-19 mRNA vaccine comprises serum cardiac troponin measurement and a 12-lead electrocardiogram (ECG). For patients with unexplained elevation of cardiac troponin and pathologic ECG, echocardiography is recommended. Consultation with a cardiovascular expert and hospitalization should be considered in this group of patients. Treatment is primarily symptomatic and supportive. Deferring a 2nd dose of the COVID-19 mRNA vaccination in individuals with suspected myocarditis or pericarditis after the 1stdose is suggested until further safety data become available. © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.